83 -5 (55) 2023 — Latipov I.I. — IMPACT ON DLQI OF A MODIFIED IMMUNOCORRECTIVE COMPLEX TREATMENT DEVELOPED USING AN EXCIMER LASER FOR PATIENTS WITH VITILIGO

IMPACT ON DLQI OF A MODIFIED IMMUNOCORRECTIVE COMPLEX TREATMENT DEVELOPED USING AN EXCIMER LASER FOR PATIENTS WITH VITILIGO

Latipov I.I. Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

For the period from 2020 to 2023, 118 patients (Group I (main group) n=60, Group II (comparison group) n=58) from patients with two clinical forms of vitiligo were examined. The study included patients of both sexes: 66 women and 52 men, aged 18 to 75 years (mean age 38.5 ± 6.8 years). In Group I (n=60), patients received combined phototherapy with narrow-band UVB therapy at 311 nm and therapy with an excimer laser with a length of 308 nm and, in addition, pentaxophylline, a minipulse corticosteroid therapy (dexamethasone) with topical therapy of 0.1% tacrolimus ointment. Group II (comparison group), where patients received combined phototherapy – narrow-band UVB therapy 311 nm and therapy with an excimer laser with a length of 308 nm. and topical therapy with tacrolimus ointment. It also greatly affects the dermatology life quality index (DLQI) of vitiligo patients.Before treatment, the mean value of DIQ was 10.9 ± 3.7 and 10.6 ± 2.0 points in both groups, which, according to the assessment scale, corresponds to a strong negative effect of the disease on the life of the patient. At the same time, the average levels of this parameter in patients of group I decreased to 2.1±0.7 points, and in Group II they were 3.3±0.4 points.

Keywords: vitiligo, immunocorrective complex therapy, excimer laser, UVB therapy, dermatology life quality index (DLQI)

First page

469

Last page

475

For citation: Latipov I.I. – IMPACT ON DLQI OF A MODIFIED IMMUNOCORRECTIVE COMPLEX TREATMENT DEVELOPED USING AN EXCIMER LASER FOR PATIENTS WITH VITILIGO //New Day in Medicine 2023 5(55): 469-475 https://newdaymedicine.com/index.php/2023/06/15/l-137/

LIST OF REFERENCES:

1. Арифов С.С., Ваисов А.Ш. Роль катехоламинов и перекисного окисления липидов в патогенезе витилиго   Вестн. дермат. 1994 3:25-27.
2. Батпенова Г.Р., Аймолдина А.А., Котлярова Т.В. и др. Значение оксидативного стресса и иммунологических расстройств при витилиго   Иммунопатология, аллергология, инфектология. 2014 4:10-14.
3. Ваисов А.Ш., Байбеков И.М., Хорошаева В. А. и др. Иммуноморфология кожи при витилиго   Сб. науч. ст. и тез. Докладов Пленума Правления ВНМОДВ. 1988 166-167.
4. Симонова Н.И., Ломоносов К.М., Бабешко О.А. Генетические аспекты витилиго (обзор литературы) Российский журнал кожных и венерических болезней. 2012 5:56-59.
5. Abd El-Samad Z., Shaaban D. Treatment of localized non-segmental vitiligo with intradermal 5-flurouracil injection combined with narrow-band ultraviolet B: a preliminary study   J. Dermatol. Treat. 2012 23(6):443-8. doi: 10.3109/09546634.2011.579084.
6. Abdurakhmanov M.M., Latipov I.I. Immune aspects of vitiligo pathogenesis and treatment  New Day in Medicine 2023 2(52):280-283 https: goo.su/08JDZy
7. Agrawal D, Shajil EM, Marfatia YS, Begum R. Study on the antioxidant status of vitiligo patients of different age groups in Baroda  Pigment Cell Res. 2004 17:289-94.
8. Attili V.R., Attili S.K. Segmental and generalized vitiligo: Both forms demonstrate inflammatory histopathological features and clinical mosaicism Indian J. Dermatol. 2013 58:433- 438.
9. Cesar Silva de Castro C., Miot H.A. Prevalence of vitiligo in Brazil-A population survey   Pigment Cell Melanoma Res. 2018 31(3):448-450.
10. Eskandani M., Golchai J., Pirooznia N., Hasannia S. Oxidative stress level and tyrosinase activity in vitiligo patients   Indian J. Dermatol. 2010 55(1):15-19.
11. Ghafouriani E, Ghafouriani S, Sadeghifard N. Vitiligo: symptoms, pathogenesis and treatment. International Journal of Immunopathology and Pharmacology 2014 27(4):485-489.
12. Kholov B., Latipov I. (2022). Vitiligo’s treatment algorithm. Models and methods in modern science, 2022 1(11):23-29.
13. Kota R.S., Vora R.V., Varma J.R. et al. Study on Assessment of Quality of Life and Depression in Patients of Vitiligo   Indian Dermatol Online J. 2019 10(2):153-157.
14. Latipov I.I. (2022). To assess the impact of vitiligo patients quality of life using the dermatological quality of life index (dlqi) questionnaire in combination therapy. European journal of modern medicine and practice, 2022 2(6):41-47.
15. Latipov I.I., Axmedovich M.F., Hamza o’g’li O. . (2021). Evaluation of the quality of life of vitiligo patients by the effectiveness of combination therapy using the dermatology life quality index (dlqi). Web of Scientist: International Scientific Research Journal, 2021 2(10):55-63.
16. Latipov I.I., Axmedovich M.F., Hamza o’g’li O.J. (2021).
17. Clinical and immunogycal aspects of pathogenesis and complex therapy of vitiligo. Academicia Globe: Inderscience Research, 2021 2(11):14-20.
18. Latipov I.I. (2022). Effectiveness of 311 nm uvb phototherapy in the treatment of vitiligo. European journal of modern medicine and practice, 2022 2(8):8-12.
19. Lee J., Chu H., Lee H. et al. A Retrospective Study of Methylprednisolone Mini-Pulse Therapy Combined with Narrow-Band UVB in Non-Segmental Vitiligo   Dermatology. 2016 232(2):224-229.Xie H., Zhou F., Liu L. et al. Vitiligo: How do oxidative stress- induced autoantigens trigger autoimmunity?   J. Dermatol. Sci. 2016 81(1):3-9.
20. Yang L., Wei Y., Sun Y. et al. Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo   Acta Derm. Venereol. 2015 95(6):664-670.